Manufacturer of Controlled Substances; Notice of Application, 73359-73360 [E7-25049]
Download as PDF
<![CDATA[
73359
Federal Register / Vol. 72, No. 247 / Thursday, December 27, 2007 / Notices
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Importer of Controlled Substances;
Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on May 31, 2007,
Innovacon, Inc., 4106 Sorrento Valley
Boulevard, San Diego, California 92121,
made application to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedule I and II:
Pursuant to Title 21 Code of Federal
Regulations 1301.34(a), this is notice
that on November 7, 2007, Johnson
Matthey, Inc., Pharmaceutical Materials,
2003 Nolte Drive, West Deptford, New
Jersey 08066–1742, made application by
renewal to the Drug Enforcement
Administration (DEA) for registration as
an importer of the basic classes of
controlled substances listed in schedule
II:
Drug
Drug
Schedule
Tetrahydrocannabinols
(7370).
3,4–
Methylenedioxymethamphetamine (MDMA)
(7405).
Heroin (9200) ..................
Cocaine (9041) ...............
Hydromorphone (9150) ...
Hydrocodone (9193) .......
Levorphanol (9220) .........
Methadone (9250) ..........
Morphine (9300) .............
Thebaine (9333) .............
Phenylacetone (8501) ..................
Raw Opium (9600) .......................
Concentrate of Poppy Staw
(9670).
I
I
I
II
II
II
II
II
II
II
mstockstill on PROD1PC66 with NOTICES
The company plans to utilize small
quantities of controlled substances to
produce drugs of abuse tests.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such substances
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), Washington, DC 20537, or any
being sent via express mail should be
sent to Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than February 25, 2008.
Dated: December 17, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–25053 Filed 12–26–07; 8:45 am]
BILLING CODE 4410–09–P
VerDate Aug<31>2005
18:00 Dec 26, 2007
Schedule
Jkt 214001
II
II
II
The company plans to import the
listed controlled substances as raw
materials for use in the manufacture of
bulk controlled substances for
distribution to its customers.
No comments, objections, or requests
for any hearings will be accepted on any
application for registration or reregistration to import crude opium,
poppy straw, concentrate of poppy
straw, or coca leaves.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances listed in schedule I or II,
which fall under the authority of section
1002(a)(2)(B) of the Act (21 U.S.C.
952(a)(2)(B)) may, in the circumstances
set forth in 21 U.S.C. 958(i), file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such comments or objections
being sent via regular mail should be
addressed, in quintuplicate, to the Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative/ODL, Washington, DC
20537, or any being sent via express
mail should be sent to Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative/ODL, 8701 Morrissette
Drive, Springfield, VA 22152; and must
be filed no later than January 28, 2008.
This procedure is to be conducted
simultaneously with and independent
of the procedures described in 21 CFR
§ 1301.34(b), (c), (d), (e) and (f). As
noted in a previous notice published in
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
the Federal Register on September 23,
1975, (40 FR 43745), all applicants for
registration to import a basic class of
any controlled substances in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e) and (f) are
satisfied.
Dated: December 18, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–25043 Filed 12–26–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on November 7, 2007,
Johnson Matthey, Inc., Custom
Pharmaceuticals Department, 2003
Nolte Drive, West Deptford, New Jersey
08066–1742, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the basic classes
of controlled substances listed in
schedule I and II:
Drug
Tetrahydrocannabinols
(7370).
Dihydromorphine (9145)
Difenoxin (9168) .............
Propiram (9649) ..............
Amphetamine (1100) ......
Methamphetamine (1105)
Methylphenidate (1724) ..
Nabilone (7379) ..............
Cocaine (9041) ...............
Codeine (9050) ...............
Dihydrocodeine (9120) ...
Oxycodone (9143) ..........
Hydromorphone (9150) ...
Ecgonine (9180) .............
Hydrocodone (9193) .......
Meperidine (9230) ...........
Methadone (9250) ..........
Methadone intermediate
(9254).
Morphine (9300) .............
Thebaine (9333) .............
Oxymorphone (9652) ......
Noroxymorphone (9668)
Alfentanil (9737) ..............
Remifentanil (9739) ........
Sufentanil (9740) ............
Fentanyl (9801) ...............
E:\FR\FM\27DEN1.SGM
27DEN1
Schedule
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
73360
Federal Register / Vol. 72, No. 247 / Thursday, December 27, 2007 / Notices
The company plans to manufacture
the listed controlled substances in bulk
for sale to its customers.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such substances
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement Administrator,
Office of Diversion Control, Federal
Register Representative (ODL),
Washington, DC 20537, or any being
sent via express mail should be sent to
Drug Enforcement Administration,
Office of Diversion Control, Federal
Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia
22152; and must be filed no later than
February 25, 2008.
Dated: December 17, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–25049 Filed 12–26–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer Of Controlled
Substances; Notice Of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on November 6, 2007,
Noramco Inc., Division of Ortho,
McNeil, Inc., 500 Swedes Landing Road,
Wilmington, Delaware 19801, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedules I and II:
mstockstill on PROD1PC66 with NOTICES
Drug
Schedule
Codeine-N-oxide (9053)
Morphine-N-oxide (9307)
Dihydromorphine (9145)
Codeine (9050) ...............
Dihydrocodeine (9120) ...
Oxycodone (9143) ..........
Hydromorphone (9150) ...
Hydrocodone (9193) .......
Morphine (9300) .............
Thebaine (9333) .............
Opium, raw (9600) ..........
Opium extracts (9610) ....
Opium fluid extract
(9620).
Opium tincture (9630) .....
Opium, powdered (9639)
Opium, granulated (9640)
Poppy Staw (9650) .........
VerDate Aug<31>2005
I
I
II
II
II
II
II
II
II
II
II
II
II
Schedule
Oxymorphone (9652) ......
Alfentanil (9737) ..............
Sufentanil (9740) ............
Carfentanil (9743) ...........
Fentanyl (9801) ...............
II
II
II
II
II
The company plans to bulk
manufacture the above listed controlled
substances for sale and distribution to
manufacturers for product development
and formulation.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement Administrator,
Office of Diversion Control, Federal
Register Representative (ODL),
Washington, DC 20537, or any being
sent via express mail should be sent to
Drug Enforcement Administration,
Office of Diversion Control, Federal
Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia
22152; and must be filed no later than
February 25, 2008.
Dated: December 17, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–25045 Filed 12–26–07; 8:45 am]
BILLING CODE 4410–09–P
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
This is notice that on November 6,
2007, Noramco Inc., 500 Swedes
Landing Road, Wilmington, Delaware
19801, made application by renewal to
the Drug Enforcement Administration
(DEA) for registration as an importer of
the basic classes of controlled
substances listed in schedule II:
Schedule
Raw Opium (9600) .........
Concentrate of Poppy
Straw (9670).
II
II
The company plans to import the
listed controlled substances to
manufacture other controlled
substances.
As noted in a previous notice
published in the Federal Register on
Jkt 214001
September 23, 1975, (40 FR 43745), all
applicants for registration to import a
basic class of any controlled substances
in schedule I or II are, and will continue
to be, required to demonstrate to the
Deputy Assistant Administrator, Office
of Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR 1301.34(b), (c), (d), (e) and (f) are
satisfied.
Dated: December 17, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–25054 Filed 12–26–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on November 12,
2007, Orasure Technologies, Inc.,
Lehigh University, Seeley G MuddBuilding 6, 220 East First Street,
Bethlehem, Pennsylvania 18015, made
application by renewal to the Drug
Enforcement Administration (DEA) as a
bulk manufacturer of the basic classes of
controlled substances listed in
schedules I and II:
Drug
DEPARTMENT OF JUSTICE
Drug
II
II
II
II
19:40 Dec 26, 2007
Drug
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
Tetrahydrocannabinols
(THC) (7370).
4–Methoxyamphetamine
(7411).
Normorphine (9313) ........
Amphetamine (1100) ......
Methamphetamine (1105)
Cocaine (9041) ...............
Oxycodone (9143) ..........
Hydromorphone (9150) ...
Benzoylecgonine (9180)
Hydrocodone (9193) .......
Meperidine (9230) ...........
Methadone (9250) ..........
Morphine (9300) .............
Schedule
I
I
I
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
to manufacture controlled substance
derivatives. These derivatives will be
used in diagnostic products created
specifically for internal use only.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such substances
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
E:\FR\FM\27DEN1.SGM
27DEN1
]]>Agencies
[Federal Register Volume 72, Number 247 (Thursday, December 27, 2007)]
[Notices]
[Pages 73359-73360]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-25049]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on November 7, 2007, Johnson
Matthey, Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive,
West Deptford, New Jersey 08066-1742, made application by renewal to
the Drug Enforcement Administration (DEA) to be registered as a bulk
manufacturer of the basic classes of controlled substances listed in
schedule I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols (7370)............... I
Dihydromorphine (9145)..................... I
Difenoxin (9168)........................... I
Propiram (9649)............................ I
Amphetamine (1100)......................... II
Methamphetamine (1105)..................... II
Methylphenidate (1724)..................... II
Nabilone (7379)............................ II
Cocaine (9041)............................. II
Codeine (9050)............................. II
Dihydrocodeine (9120)...................... II
Oxycodone (9143)........................... II
Hydromorphone (9150)....................... II
Ecgonine (9180)............................ II
Hydrocodone (9193)......................... II
Meperidine (9230).......................... II
Methadone (9250)........................... II
Methadone intermediate (9254).............. II
Morphine (9300)............................ II
Thebaine (9333)............................ II
Oxymorphone (9652)......................... II
Noroxymorphone (9668)...................... II
Alfentanil (9737).......................... II
Remifentanil (9739)........................ II
Sufentanil (9740).......................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
[[Page 73360]]
The company plans to manufacture the listed controlled substances
in bulk for sale to its customers.
Any other such applicant and any person who is presently registered
with DEA to manufacture such substances may file comments or objections
to the issuance of the proposed registration pursuant to 21 CFR
1301.33(a).
Any such written comments or objections being sent via regular mail
should be addressed, in quintuplicate, to the Drug Enforcement
Administrator, Office of Diversion Control, Federal Register
Representative (ODL), Washington, DC 20537, or any being sent via
express mail should be sent to Drug Enforcement Administration, Office
of Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than February 25, 2008.
Dated: December 17, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E7-25049 Filed 12-26-07; 8:45 am]
BILLING CODE 4410-09-P
